^
BIOMARKER:

BRAF wild-type

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
Related biomarkers:
BRAF wild-type
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
BRAF wild-type
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF wild-type
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
BRAF wild-type
Colon Cancer
cetuximab
Sensitive: A2 - Guideline
BRAF wild-type
Colon Cancer
panitumumab
Sensitive: A2 - Guideline
BRAF wild-type
Melanoma
nivolumab
Sensitive: B - Late Trials
BRAF wild-type
CRC
bevacizumab
Sensitive: B - Late Trials
BRAF wild-type
Melanoma
selumetinib
Sensitive: C2 – Inclusion Criteria
BRAF wild-type
Melanoma
trametinib
Sensitive: C2 – Inclusion Criteria
BRAF wild-type
CRC
cetuximab
Sensitive: C2 – Inclusion Criteria
BRAF wild-type
CRC
anlotinib
Sensitive: C2 – Inclusion Criteria
BRAF wild-type
CRC
panitumumab
Sensitive: C2 – Inclusion Criteria
BRAF wild-type
CRC
CPGJ-602
Sensitive: C2 – Inclusion Criteria
BRAF wild-type
Melanoma
pembrolizumab + trametinib
Sensitive: C3 – Early Trials
BRAF wild-type
Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
BRAF wild-type
Melanoma
dacarbazine
Sensitive: C4 – Case Studies